News: Quintiles Transnational Holdings Inc (Q.N)
Q.N on New York Stock Exchange
46.29USD
1 Aug 2013
46.29USD
1 Aug 2013
Price Change (% chg)
$1.44 (+3.21%)
$1.44 (+3.21%)
Prev Close
$44.85
$44.85
Open
$46.30
$46.30
Day's High
$47.49
$47.49
Day's Low
$45.52
$45.52
Volume
143,922
143,922
Avg. Vol
--
--
52-wk High
$47.49
$47.49
52-wk Low
$41.50
$41.50
Select another date:
Thu, Aug 1 2013
Quintiles sees strong profit as drug development picks up
- Quintiles Transnational Holdings, the world's largest medical contract research provider, forecast full-year profit above market expectations as drugmakers looking to launch new products choose to outsource clinical development as a way to cut costs.
UPDATE 1-Quintiles profit rises as drug developers outsource research
* Sees 2013 service revenue $3.76 bln-$3.81 bln vs est $3.81 bln
KKR funds to buy clinical trial firm PRA International
June 24 - Funds managed by KKR & Co LP will buy clinical research group PRA International from Genstar Capital LLC for an undisclosed amount, PRA said on Monday, underscoring growing private equity interest in the contract research industry.
Select another date:
- Quintiles Transnational Holdings' CEO Discusses Q2 2013 Results - Earnings Call Transcript
- Analysts' Actions: CRL CVLT LNKD Q WETF
- Cramer's Lightning Round - I Should Have Gone Back To Dover (5/30/13)
- 'Mad Money' Lightning Round: Still Waiting on McDonald's
- Quintiles At $45 Still Holds Value
- Covance Not Cooling Off
Press Releases
- Quintiles Reports Second Quarter 2013 Results and Full Year 2013 Guidance
- Health Care Executives Say Collaboration Improves Outcomes, But Find Success Elusive
- Quintiles’ Second Quarter 2013 Earnings Call Scheduled for Thursday, August 1st
- Quintiles Named a Best Workplace in Europe
- Quintiles Named Britain’s Healthiest Large Company
- Quintiles Transforms Laboratory Management for Investigator Sites with Quintiles Infosario® Platform
- Quintiles Named a “Best Place to Work in IT” by Computerworld for Fifth Time
- Quintiles Receives Award from Patient-Centered Outcomes Research Institute to Compare the Effectiveness of Uterine Fibroid Treatments in Real-World Practice
- Quintiles Releases Perspectives on Early Phase Oncology and Hematology Biomarkers
- Quintiles Rated Industry Leader and Highest in Service Quality in Phase II/III Clinical Research

